Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 4/20 | 0.55 |
| ▸ | EIF4H | Q15056 | 4/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14657342 | 0.92 | PTPN1 (0.57) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28173001 | 0.86 | P2RX7 (0.55) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8154848 | 0.83 | TRPV1 (0.66) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL13459508 | 0.83 | MEN1 (0.54) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14267990 | 0.83 | MEN1 (0.54) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8620986 | 0.81 | MEN1 (0.73) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14183610 | 0.80 | SMN1; SMN2 (0.66) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL27489211 | 0.79 | MEN1 (0.71) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1312094 | 0.79 | TRPV1 (0.74) | MEN1KMT2AALDH1A1KDM4ETRPV1 | |
| SCHEMBL2398063 | 0.79 | KDR (0.63) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| EP-3888749-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2021-10-06 | — | — | EP | disclosed |
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2021-09-28 | — | — | US | disclosed |
| CN-107108593-B | Substituted oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II | 美迪福伦DBT有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3578547-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2019-12-11 | — | — | EP | disclosed |
| EP-3224252-B1 | SUBSTITUTED OXAZOLE- AND THIAZOLE-BASED CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS II | MEDIFRON DBT INC (KR) | 2019-01-09 | — | — | EP | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| US-9771359-B1 | Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II | MEDIFRON DBT INC. (KR) | 2017-09-26 | — | — | US | disclosed |
| US-20170253586-A1 | Substituted Oxazole- and Thiazole-Based Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands II | MEDIFRON DBT INC. (KR) | 2017-09-07 | — | — | US | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010023512-A1 | NOVEL VANILLOID RECEPTOR MODULATORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MATRIX LABORATORIES LTD. (IN) | 2010-03-04 | — | — | WO | disclosed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1836211-A1 | MACROLIDES | Pfizer Products Incorporated (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006067589-A1 | MACROLIDES | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135447-A1 | Macrolides | CHUPAK LOUIS S | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | MEN1 4202/4885KMT2A 4317/4885ALDH1A1 3407/4885 |
| US-20060135447-A1 | Macrolides | LCAT, NOP2, HDAC6 | MEN1 3829/4885KMT2A 2668/4885ALDH1A1 3275/4885 |
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | NLRP3, PYCARD, IAPP | MEN1 3639/4885KMT2A 4072/4885ALDH1A1 3558/4885 |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | MEN1 3639/4885KMT2A 4072/4885ALDH1A1 3558/4885 |
| US-20170253586-A1 | Substituted Oxazole- and Thiazole-Based Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands II | TRPV1, TRPV2, GPR17 | MEN1 4833/4885KMT2A 3700/4885ALDH1A1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.